0 Comments Click here to read/write comments
Topics: clinical trials, Phase I/II clinical trials, FDA approval
Biostar Stem Cell Research institute has developed a protocol for the use of autologous [the patient’s own] stem cells to combat Alzheimer’s Disease with the FDA has approving Phase I and II clinicals trials for the new treatment. The process involves recovering, isolating and culturing the patient’s own stem cells. Culturing the cells results in the production of a clinically significant number of cells, enabling an extended treatment period and protocol. These cells are injected intravenously across ten treatments, using approximately 200 million cells each time. By utilizing the patient’s own stem cells to address neural degradation, the researchers anticipate the treatment may go a long way to both slow the degenerative progression of the disease, while also addressing the root cause of Alzheimer’s Disease.
0 Comments Click here to read/write comments
Topics: Alzheimer's disease, Phase I/II clinical trials, FDA approval, regenrative medicine
A Phase I/II clinical trial to treat dry age-related macular degeneration (Dry-AMD) is being conducted by StemCells, Inc. Dry-AMD is the most common type of macular degeneration and affects 90% of patients with the condition. It is a chronic eye disease that causes vision loss in the center of the field of vision and is the major cause of blindness and visual impairment in adults older than 50.
0 Comments Click here to read/write comments
Topics: Phase III, neural stem cells, stemsaveblog, clinical trials, dry age-related macular degeneration, Stemcells, Phase I/II clinical trials, clinical trial, Dry AMD, StemCells Inc., AMD
